Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases-Reference-Cited by-同舟云学术

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases

Published:2016-06-07 Issue:7 Volume:30 Page:453-460
ISSN:0914-7187
Container-title:Annals of Nuclear Medicine
language:en
Short-container-title:Ann Nucl Med

Author:

Yoshida Keisuke,Kaneta Tomohiro,Takano Shoko,Sugiura Madoka,Kawano Tsuyoshi,Hino Ayako,Yamamoto Tou,Shizukuishi Kazuya,Kaneko Masato,Zurth Christian,Inoue Tomio

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12149-016-1093-8.pdf

Reference17 articles.

1. Turner PG, O’Sullivan J. Radium-223 dichloride for the treatment of metastatic prostate cancer. Expert Opin Pharmacother. 2014;15(14):2105–11.

2. 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA Study 9. Clin Adv Hematol Oncol. 2014;12(4 Suppl 11):9–10.

3. Anido Herranz U, Fernandez Calvo O, Afonso Afonso FJ, Rodriguez Martinez de Llano S, Lazaro Quintela M, Leon Mateos L et al. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015; 1–10.

4. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406.

5. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738–46.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for²²³Ra-Based Radiopharmaceutical Therapies;Journal of Nuclear Medicine;2024-04-04

2. Comparison Of Alpha and X-ray Irradiation Effects in nMAG Polymer Gels Used for Dosimetry Applications;Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms;2024-04

3. Micellar solution of [223Ra]RaCl2: Reaching renal excretion, potent efficacy in osteoblastic osteosarcoma in PDX model, biochemistry alterations and pharmacokinetics;International Journal of Pharmaceutics;2024-03

4. Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis;Frontiers in Medicine;2023-02-08

5. Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [223Ra]RaCl2 and [224Ra]RaCl2;Frontiers in Medicine;2023-01-04